EQ News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$75.8M

Volume

459.14K

Next Earnings

November 12th

Mkt Cap

$83.7M

Volume

459.14K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Wereldhave, through Wereldhave Belgium, acquires supermarket unit and completes ownership of shopping center Ville2 in CharleroiWereldhave Belgium has acquired a supermarket anchor unit in shopping center Ville2 in Charleroi, achieving 100% ownership of the property. The acquisition was financed through newly issued Wereldhave N.V. shares at market value and will have a slightly positive impact on the group's LTV ratio, reducing it by 10 basis points to 42.4%.GlobeNewswire Inc. · Mar 11, 2026

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025Equillium will host a virtual key opinion leader event discussing unmet needs in ulcerative colitis treatment, featuring experts who will explore the potential of AhR modulation and the company's EQ504 therapeutic approach.GlobeNewswire Inc. · Oct 22, 2025

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.The Motley Fool · Sep 3, 2025

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsightThe graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.GlobeNewswire Inc. · Sep 22, 2024

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide TherapyVivtex and Equillium have entered a research collaboration to develop an optimized oral version of Equillium's EQ302, a bi-specific peptide inhibitor of IL-15 and IL-21, for the treatment of gastrointestinal disorders.GlobeNewswire Inc. · Sep 16, 2024

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue EstimatesEquillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

Alector (ALEC) Reports Q1 Loss, Tops Revenue EstimatesAlector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 8, 2024

5 Stocks That More Than Doubled in Q1 With More Gains AheadEquillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.Zacks Investment Research · Apr 1, 2024

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionShares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share. Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Stoke Therapeutics, Inc. (NASDAQ: STOK) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. C3is Inc. (NASDAQ: CISS) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-quarter financial results. OpGen, Inc. (NASDAQ: OPGN) shares climbed 48.2% to $0.7039 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million. Mesoblast Limited (NASDAQ: MESO) gained 43.2% to $3.1501. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory acute graft versus host disease. Praxis Precision Medicines Inc (NASDAQ: PRAX) gained 31.9% to $66.63 after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. Nuvation Bio Inc (NYSE: NUVB) climbed 24.4% to $2.80 after BTIG upgraded the stock from Neutral to Buy. Check-Cap Ltd. (NASDAQ: CHEK) shares gained 24.3% to $2.40 after the company announced that it entered into a definitive Business Combination Agreement with Nobul AI. Viking Therapeutics ...Benzinga · Mar 26, 2024

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue EstimatesEquillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Mar 25, 2024

EQEquillium, Inc. Common Stock

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any EQ yet.

Related Tickers

Earnings

Mkt Cap

$75.8M

Volume

459.14K

Next Earnings

November 12th